口服司美格鲁肽的心血管获益:SOUL试验中基线或HbA1c与BMI变化的影响
SOUL试验事后分析纳入9650例≥50岁伴动脉粥样硬化性心血管病和/或慢性肾脏病的2型糖尿病成人,随机接受口服司美格鲁肽或安慰剂,随访47.5个月。口服司美格鲁肽降低主要不良心血管事件(MACE)风险14%,其获益在基线HbA1c较高者中更显著,且与试验期间HbA1c降幅更大相关,但与基线或BMI变化无关。
要点
- 口服司美格鲁肽降低MACE风险14%,基线HbA1c越高获益越明显。
- 试验期间HbA1c降幅越大,MACE风险降低越多。
- BMI基线或变化不影响口服司美格鲁肽的心血管获益。
核心结论
- 口服司美格鲁肽的心血管获益在基线HbA1c较高及HbA1c降幅较大的患者中更明显,但与基线或BMI变化无关。
研究设计与样本
- SOUL试验(NCT03914326)的事后分析,双盲、安慰剂对照,2019至2024年,国际444个中心。
- 纳入9650例≥50岁、伴动脉粥样硬化性心血管病和/或慢性肾脏病的2型糖尿病成人,1:1随机接受口服司美格鲁肽或安慰剂,随访47.5个月。
主要发现
- 口服司美格鲁肽使MACE风险降低14%。
- MACE获益在不同基线BMI类别间一致。
关键数值与推荐
- 基线HbA1c均值(±SD)为8.0(1.1)%(63.5±12.5 mmol/mol),BMI为31.1(5.8)kg/m2。
- 中位(IQR)年龄为66(61-72)岁。
临床怎么用
- 对于基线HbA1c较高的2型糖尿病合并心血管病或慢性肾脏病患者,口服司美格鲁肽可能带来更明显的心血管获益。
- 实现更大的HbA1c降幅可能与更显著的心血管风险降低相关。
- BMI的基线水平或变化不宜作为预测口服司美格鲁肽心血管获益的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In the SOUL trial (NCT03914326), oral semaglutide reduced risk of major adverse cardiovascular (CV) events (MACE) by 14%. Whether baseline or changes in HbA1c or BMI are associated with these CV benefits is not known. OBJECTIVE: We evaluated whether CV benefits of oral semaglutide are associated with baseline or in-trial reductions in HbA1c or BMI. DESIGN: Post hoc analysis of SOUL, a double-blind, placebo-controlled trial (2019‒2024). SETTING: International, 444 sites. PARTICIPANTS: Adults aged ≥50 years, with type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease. INTERVENTION(S): Oral semaglutide or placebo. MAIN OUTCOME MEASURES: 3-point MACE (CV death, nonfatal myocardial infarction, or nonfatal stroke) analyzed by baseline and in-trial changes in HbA1c and BMI (Weeks 13; 52). RESULTS: 9650 adults randomized 1:1 to oral semaglutide or placebo were followed for 47.5 months. Median (IQR) age was 66 (61-72) years, mean (±SD) HbA1c 8.0 (1.1)% (63.5±12.5 mmol/mol) and BMI 31.1 (5.8) kg/m2. MACE benefits from oral semaglutide were significantly different across baseline HbA1c categories (P-interaction = .04), suggesting greater risk reduction at higher baseline HbA1c, but were consistent across baseline BMI categories. Greater in-trial HbA1c reductions were associated with larger decreases in MACE risk with oral semaglutide at 13 and 52 weeks (P-interactions .005 and < .001, respectively), whereas BMI changes showed consistency (P-interactions .88 and .64, respectively). CONCLUSIONS: In SOUL, CV benefits of oral semaglutide appeared more pronounced among participants with higher baseline HbA1c and greater HbA1c reductions, but were consistent across baseline or changes in BMI.
引用
- Inzucchi SE, Abdul Ghani R, Deanfield J, et al. Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes? J Clin Endocrinol Metab. 2026. PMID: 42478869. doi:10.1210/clinem/dgag290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。